RESULTS	After a median follow-up of 55.7 months ( range 0-89 .7 ) , 809 events contributing to the analysis of disease-free survival had been reported ( 354 exemestane , 455 tamoxifen ) ; unadjusted hazard ratio 0.76 ( 95 % CI 0.66-0 .88 , p = 0.0001 ) in favour of exemestane , absolute benefit 3.3 % ( 95 % CI 1.6-4 .9 ) by end of treatment ( ie , 2.5 years after randomisation ) .\